J&J raises 2026 guidance, projecting $100.5B revenue
Johnson & Johnson posted another strong quarter, with revenue rising UP 9% to $24.6 billion, beating the $24.1 billion FactSet consensus as its oncology pivot continues to pay off.
The company’s momentum was led by two key multiple myeloma treatments, Darzalex and Carvykti, which have become central to CEO Joaquin Duato’s strategy, reports Market Watch.
Darzalex alone delivered $3.9 billion in Q4 sales, UP from $3.1 billion a year earlier and above the $3.7 billion estimate. J&J has openly said it wants to become the world’s top cancer drugmaker by 2030, targeting $50 billion in oncology revenue by then. Duato has framed myeloma as a category J&J wants to dominate, telling investors the goal is to have “four out of five” patients using at least one J&J product in their regimen. The broader plan narrows the company’s “innovative medicine” priorities to oncology, immunology, and neuroscience, while medtech focuses on cardiovascular, surgical, and vision care.
Profit misses expectations as restructuring and strategy shifts take hold
Despite the revenue strength, J&J’s profitability came in weaker than analysts expected, signaling that the company’s transition phase still carries costs. Net income landed at $5.1 billion, higher than last year’s $3.4 billion but below the $5.9 billion consensus estimate. Shares slipped about DOWN 2% in premarket trading after the report, even with solid top-line execution. J&J is also reshaping its business model under Duato, including plans to spin off its orthopedic device unit, which represents around 10% of total revenue.
That shift is designed to streamline the company and concentrate resources around its six core areas, with oncology at the center. Still, adjusted earnings per share came in at $2.46, matching expectations once acquisition-related and nonrecurring items were excluded. The company said this adjusted metric reflects, among other factors, the impact of its recent move to acquire cancer biotech Halda Therapeutics.
2026 outlook signals confidence, and the stock reflects a bullish rerating
J&J raised its forward outlook, projecting $100.5 billion in 2026 revenue and adjusted EPS of $11.53, both above what it delivered in 2025. That compares with $94.2 billion in 2025 revenue and adjusted EPS of $11.03, showing the company expects growth to continue accelerating into the new year. The new guidance also tops Street expectations, with FactSet consensus at $98.94 billion for revenue and $11.48 for EPS in 2026. Duato recently told investors he expects J&J to do “better in 2026 than in 2025,” and said visibility later in the decade supports double-digit growth. The market has largely backed that narrative so far, with J&J shares gaining UP 47% over the past year versus the S&P 500 UP 12%. The stock closed at a record $219.57 on Jan. 15, underscoring how strongly investors are pricing in the oncology-led strategy.
Recently we wrote that Johnson & Johnson is set to release its fourth-quarter fiscal 2025 results before the market opens on January 21, drawing investor focus to upcoming guidance and developments in its drug and medical device divisions.
Latest Johnson & Johnson News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
